Treatment News : FDA Updates the Labels of Intelence (Etravirine) and Prezista (Darunavir)

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 5, 2013

FDA Updates the Labels of Intelence (Etravirine) and Prezista (Darunavir)

The U.S. Food and Drug Administration has approved changes to the labels for the antiretrovirals (ARVs) Intelence (etravirine) and Prezista (darunavir).

The changes to the Intelence label are as follows:

  • There have been reports of severe, potentially life-threatening and fatal skin reactions. Among these are Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme.
  • Hypersensitivity reactions include Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), characterized by rash and sometimes organ dysfunction, including liver failure.
  • Grade three and four rash occurred in about 1 percent of those taking Prezista in a Phase III trial. Women were more likely than men to experience rash, which occurred most commonly during the first 6 weeks of therapy. A total of 2.2 percent of those in the Phase III trial discontinued therapy due to rash.
  • Drug interactions include:
    • Antimalarials: artemether/lumefantrine. Caution is advised when taking Intelence with artemether/lumefantrine because it is not known whether Intelence may reduce antimalarial efficacy.
    • Hepatitis C virus (HCV) direct-acting antivirals: telaprevir. The combination leads to no change in Intelence levels, but it does lead to a decrease in telaprevir. There are insufficient data to make a dosing advisement for telaprevir in combination with Intelence.
The changes to the Prezista label include:
  • Antimalarials: artemether/lumefantrine. Prezista can be used without dose adjustments, but the combination should be used with caution because an increase of lumefantrine exposure may raise the risk of QT prolongation (irregular heart rhythm).
To read the FDA release on Intelence, click here.

To read the FDA release on Prezista, click here.

Search: Intelence, Etravirine, Prezista, Darunavir, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, Drug Rash with Eosinophilia and Systemic Symptoms, DRESS, Antimalarials, artemether/lumefantrine, Hepatitis C virus, HCV, direct-acting antiviral, telaprevir, QT prolongation.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.